论文部分内容阅读
目的 探讨p16蛋白缺失与脑胶质瘤的恶性进展、增殖能力及预后的关系。方法 应用免疫组织化学方法 ,检测了96例不同级别脑胶质瘤存档标本 p16蛋白及增殖细胞核抗原的表达情况。 结果 p16蛋白缺失频率随脑胶质瘤级别的增高而增高 (P <0 .0 1) ;4对复发时级别增高的肿瘤组织均发生了 p16蛋白缺失 ,而另 3对复发时仍保持原来级别者无一发生p16蛋白缺失。同一级别的脑胶质瘤 ,p16蛋白缺失者的PCNA指数明显高于无 p16蛋白缺失者 (P <0 .0 5 )。 结论 p16蛋白缺失与脑胶质瘤的恶性进展及增殖能力有关 ,p16蛋白免疫组织化学检测可作为反映脑胶质瘤预后的 1个指标。
Objective To investigate the relationship between the loss of p16 protein and malignant progression, proliferation and prognosis of glioma. Methods Immunohistochemistry was used to detect the expression of p16 protein and proliferating cell nuclear antigen in 96 specimens of different grades of glioma. Results The frequency of deletion of p16 protein increased with the increase of glioma grade (P <0.01). The deletion of p16 protein was observed in all the 4 tumors with high grade recurrence, while the other three groups remained the same None of the p16 proteins were deleted. The same level of gliomas, p16 protein deletion in PCNA index was significantly higher than those without p16 protein deletion (P <0.05). Conclusion The loss of p16 protein is associated with the malignant progression and proliferation of gliomas. The immunohistochemical detection of p16 protein may be used as an index to reflect the prognosis of gliomas.